LYRA is expected to report earnings to rise 6.94% to -19 cents per share on March 05
Q4'24
Est.
$-0.19
Q3'24
Beat
by $0.04
Q2'24
Missed
by $0.41
Q1'24
Missed
by $0.09
Q4'23
Beat
by $0.13
The last earnings report on November 12 showed earnings per share of -18 cents, beating the estimate of -21 cents. With 1.90M shares outstanding, the current market capitalization sits at 12.37M.
a clinical-stage therapeutics company, which develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases